Senores Pharmaceuticals Limited has announced a strategic joint venture in the United States, marking a significant expansion into the federal government procurement market. The partnership was formalized through an Operating Agreement executed on April 2, 2026, establishing Amerisyn, LLC as the joint venture entity.

Strategic Partnership Details

The joint venture has been established through Senores Pharmaceuticals, Inc., the company's wholly owned subsidiary in the United States. This strategic alliance represents a decisive milestone in the company's international expansion efforts and creates a pathway for accessing U.S. government contracts.

Market Access and Opportunities

The partnership strategically positions Senores to facilitate supply of its pharmaceutical product portfolio to multiple government sectors:

• U.S. Federal Government contracts
• Veterans affairs supply agreements
• Military supply contracts
• Long-term national contracts
• Government supply tenders

This joint venture framework provides the company with specialized credentials necessary to participate in the high-entry-barrier U.S. government procurement market.

Management Perspective

Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, emphasized the significance of this development: "Amerisyn is a major milestone for Senores. This will enable Senores to utilise its manufacturing and product expertise for supply to the U.S. government sector and unlock a high-entry-barrier market. We expect this partnership to be a significant driver of growth and a substantial contributor to our international business volumes moving forward."

Company Portfolio and Capabilities

Senores Pharmaceuticals operates as a global, research-driven pharmaceutical company with extensive manufacturing capabilities across multiple markets. The company's current portfolio includes:

Manufacturing Infrastructure

The company operates five manufacturing facilities strategically located across different regions:

Formulation Facilities:

• Atlanta, US: USFDA approved, DEA, TAA & BAA compliant for controlled substances and government supplies
• Baroda: USFDA, Health Canada and UKMHRA approved site
• Chhatral, Ahmedabad: WHO-GMP approved for emerging markets

API Manufacturing:

• Two facilities in India, both located around Ahmedabad (Chhatral and Naroda)

The company also maintains strong research and development capabilities across three R&D sites, with one facility in the USA and two in India, supporting its differentiated product portfolio development across various therapeutic areas and dosage forms.

Senores Pharmaceuticals Limited has filed a comprehensive regulatory disclosure under SEBI SAST regulations following the successful allotment of 11,70,000 convertible warrants worth ₹95.00 crore. The disclosure was submitted by promoter Swapnil Jatin Shah on behalf of all promoter and promoter group entities on April 01, 2026.

Warrant Allotment Structure

The company completed the allotment of warrants at an exercise price of ₹812.00 per warrant, aggregating to ₹95,00,40,000. The subscription amount received was ₹203.00 per warrant, representing 25% of the issue price and totaling ₹23,75,10,000. The remaining ₹609.00 per warrant will be payable upon conversion within 18 months.

SAST Regulatory Compliance

The disclosure filed under Regulation 29(2) of SEBI SAST Regulations provides detailed shareholding information for all promoter and promoter group entities. The warrants were allotted through preferential issue on March 28, 2026, with the regulatory filing submitted to both BSE (Scrip Code: 544319) and NSE (Symbol: SENORES).

Detailed Investor Allocation

The warrants were distributed among five promoter and promoter group entities, with Renosen Pharmaceuticals Private Limited receiving the largest allocation. The comprehensive allocation details show the strategic distribution among key stakeholders.

Comprehensive Shareholding Impact

The SAST disclosure reveals the complete promoter and promoter group shareholding structure, including entities like Remus Pharmaceuticals Limited, Aviraj Overseas LLC, and Espee Therapeutics LLP. The total promoter and promoter group holding stands at 2,11,00,357 shares representing 45.82% of the current share capital.

Capital Structure and Compliance

The allotment maintains compliance with all regulatory requirements under SEBI LODR and ICDR regulations. The warrants carry conversion rights to equity shares with a face value of ₹10.00 each and are subject to prescribed lock-in restrictions. The disclosure confirms that no shares are under encumbrance and no voting rights exist other than through equity shareholding.

The formal documentation was digitally signed by Swapnil Jatin Shah as the designated promoter representative, ensuring complete regulatory compliance and transparency in the preferential allotment process.